Nutraceutical treatments for diabetic and non-diabetic wound healing
View Patent ↗In an embodiment of the present invention, a nutraceutical formula comprising a combination of chromium, zinc, berry extract, Polygonum cuspidatum extract, aloe vera, chlorophyll and L-arginine combined synergistically to reduce inflammation in mammals suffering from diabetes. In another embodiment of the present invention, a nutraceutical formula comprising a of zinc, chromium, berry extract, Polygonum cuspidatum extract, aloe vera, chlorophyll and L-arginine combined synergistically to enhance wound healing in mammals suffering from diabetes. In an alternative embodiment of the present invention, a nutraceutical formula comprising a of zinc, chromium, berry extract, Polygonum cuspidatum extractive, aloe vera, chlorophyll and L-arginine combined synergistically to reduce inflammation in mammals not suffering from diabetes. In another embodiment of the present invention, a nutraceutical formula comprising a combination of zinc, chromium, berry extract, Polygonum cuspidatum extractive, aloe vera, chlorophyll, and L-arginine combined synergistically to enhance wound healing in mammals not suffering from diabetes.
1. A composition for administration to reduce inflammation and enhance wound healing in a mammal, the composition comprising:
an amount of chromium between:
a lower limit of approximately 10 μg human equivalency dosage (HED) per day; and
an upper limit of approximately 1000 μg HED per day;
an amount of zinc between:
a lower limit of approximately 1.5 mg HED per day; and
an upper limit of approximately 75 mg HED per day;
an amount of berry extract comprising anthocyanins between:
a lower limit of approximately 3 mg HED per day; and
an upper limit of approximately 500 mg HED per day;
an amount of Polygonum cuspidatum extract between:
a lower limit of approximately 1.5 mg HED per day; and
an upper limit of approximately 100 mg HED per day;
an amount of trans-resveratrol between:
a lower limit of approximately 0.1 mg HED per day; and
an upper limit of approximately 50 mg HED per day;
an amount of 1-arginin between:
a lower limit of approximately 50 mg HED per day; and
an upper limit of approximately 1000 mg HED per day;
an amount of chlorophyllin between:
a lower limit of approximately 10 mg HED per day; and
an upper limit of approximately 300 mg HED per day.
2. The composition of claim 1 which is for topical application and further comprises:
an amount of aloe Barbendisis miller between:
a lower limit of approximately 0.01 % (by weight);
an upper limit of approximately 10 % (by weight).